Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor

Patent metadata

Field	Value
Publication number	US-10517866-B2
Application number	US-201815981696-A
Country	US
Kind code	B2
Filing date	May 16, 2018
Priority date	Jan 28, 2014
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

First claim

The invention claimed is:

1. A method for killing a senescent cell in vitro, comprising contacting the cell with an effective amount of a means for binding to and directly inhibiting phosphoinositide 3-kinase (PI3k),
wherein the senescent cell is defined as a p16 positive cell that is not a cancer cell, and
wherein the amount of the means for binding to and directly inhibiting PI3k is effective in promoting apoptosis in the senescent cell, thereby killing the cell.

2. The method of claim 1 , wherein the means for inhibiting PI3k is apitolisib (GDC-0980) or a pharmaceutically effective salt thereof.

3. The method of claim 1 , wherein the means for inhibiting PI3k is BKM120 or a pharmaceutically effective salt thereof.

4. The method of claim 1 , wherein the means for inhibiting PI3k is selected from perifosine (KRX-0401), idelalisib, PX-866, IPI-145, BAY 80-6946, BEZ235, RP6530, TGR 1201, SF1126, INK1117, GDC-0941, XL147 (SAR245408), XL765 (SAR245409), Palomid 529, GSK1059615, GSK690693, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, RP6503, PI-103, GNE-477, CUDC-907, AEZS-136, BYL719, GDC-0032, and pharmaceutically acceptable salts thereof.

5. The method of claim 1 , wherein the senescent cell is a fibroblast.

6. A method for selectively removing senescent cells from a target tissue in a subject in need thereof, comprising treating the subject according to a clinical protocol that includes:
(1) a treatment period, during which senescent cells in the target tissue are contacted with an effective amount of a senolytic compound in one or more doses, wherein the amount of the senolytic compound is effective in reducing the number of senescent cells in the target tissue from a pre-treatment level to a post-treatment level; and
(2) a subsequent non-treatment interval, during which further treatment with the senolytic compound is withheld from the subject;
wherein the senolytic compound is a means for binding to and directly inhibiting phosphoinositide 3-kinase (PI3k),
wherein the senescent cells are defined as p16 positive cells that are not cancer cells;
wherein the duration of the non-treatment interval has been established as a time during which the number of senescent cells in the target tissue will remain below the pre-treatment level; and
wherein the duration of the non-treatment interval is at least two weeks.

7. The method of claim 6 , wherein the means for inhibiting PI3k is selected from apitolisib (GDC-0980), BKM120, and pharmaceutically acceptable salts thereof.

8. The method of claim 6 , wherein the means for inhibiting PI3k is selected from perifosine (KRX-0401), idelalisib, PX-866, IPI-145, BAY 80-6946, BEZ235, RP6530, TGR 1201, SF1126, INK1117, GDC-0941, XL147 (SAR245408), XL765 (SAR245409), Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, RP6503, PI-103, GNE-477, CUDC-907, AEZS-136, BYL719, GDC-0032, and pharmaceutically acceptable salts thereof.

9. The method of claim 6 , wherein the target tissue is an atherosclerotic plaque.

10. The method of claim 6 , further comprising determining the number of senescent cells in the target tissue after administering the senolytic compound.

11. A method for reducing the number of senescent cells in a mixed cell population or tissue, comprising administering to the mixed cell population or tissue an effective amount of a senolytic compound,
wherein the senescent cells are defined as p16 positive cells that are not cancer cells,
wherein the senolytic compound is a means for binding to and directly inhibiting phosphoinositide 3-kinase (PI3k),
wherein the mixed cell population or tissue is a population of cells cultured in vitro; and wherein the amount of the means for binding to and directly inhibiting PI3k is effective in promoting apoptosis in the p16-positive cells, thereby selectively removing at least some of the p16-positive cells from the mixed cell population or tissue.

12. The method of claim 11 , further comprising determining the number of senescent cells in the mixed cell population after administering the senolytic compound.

13. A method for selectively removing senescent cells from a mixed cell population or tissue, comprising treating the mixed cell population or tissue with a treatment protocol that includes:
(1) a treatment period, during which senescent cells in the mixed cell population or tissue are contacted with an effective amount of a senolytic compound in one or more doses, wherein the amount of the senolytic compound is effective in reducing the number of senescent cells in the mixed cell population or tissue from a pre-treatment level to a post-treatment level; and
(2) a subsequent non-treatment interval, during which further treatment of the mixed cell population or tissue with the compound is withheld;
wherein the senolytic compound is a means for binding to and directly inhibiting phosphoinositide 3-kinase (PI3k),
wherein the senescent cells are defined as p16 positive cells that are not cancer cells,
wherein the amount of the compound used during the treatment period is also effective in causing the number of senescent cells in the target tissue to remain below the pre-treatment level throughout the non-treatment interval; and
wherein the duration of the non-treatment interval is at least two weeks.

14. The method of claim 13 , wherein the mixed cell population or tissue is contacted with the senolytic compound in vitro.

15. The method of claim 13 , wherein the mixed cell population or tissue is contacted with the senolytic compound in vivo in a target tissue in a subject in need thereof.

Assignees

• Unity Biotechnology Inc
• Buck Inst Res Aging
• Mayo Found Medical Education & Res

Inventors

• Laberge Remi-Martin
• Kirkland James L
• Tchkonia Tamar
• Zhu Yi
• David Nathaniel
• Vasserot Alain Philippe
• Baker Darren J
• Childs Bennett G
• Van Deursen Jan M A

Classifications

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title